Life Science Investment In China Reaches Record High

Last year was an excellent year for China’s life science industry, with investment in the sector reaching an all-time high.

More than $43 billion (£34 billion) was raised for new venture capital and private equity funds in China’s life science investments in 2018, according to a report in MedCityNews.com.

This takes the total level of investments in the industry in the Asian nation to $765 million, figures complied by ChinoBio and presented at the China Showcase in San Francisco recently revealed.

Additionally, $17 billion was invested in China’s life science companies last year, which is a 36 per cent increase from 2017’s level of funding.

It is thought the improved regulatory system at the CFDA (China Food and Drug Administration), including its new expedited review and approvals, is the reason behind the expansion of the industry, with more companies encouraged to invest in a well-regulated sector.

According to ChinaBio, 2018 was a “golden era of healthcare in China”, thanks mainly to government support with $100 billion invested in improving healthcare policies; more than two million talented employees; and a 6.5 per cent growth in GDP during H1 2017.

All of these factors have boosted the “sea of change” for the industry in China, encouraging significant investment from other organisations.

One of the most important ways of boosting the life science business, whether in China or the UK, is to focus on the marketing and promotion of breakthroughs and developments.

Here at Voicentric, we can provide excellent life science telemarketing services to raise awareness of organisations’ latest projects, which could increase funding in them in the future.